Recent Investment Analysts’ Ratings Updates for FibroGen (FGEN)

A number of research firms have changed their ratings and price targets for FibroGen (NASDAQ: FGEN):

• 12/24/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/17/2024 – FibroGen was upgraded by analysts at HC Wainwright to a “strong-buy” rating.
• 12/16/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/8/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/30/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/22/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/14/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/13/2024 – FibroGen had its “market perform” rating reaffirmed by analysts at William Blair.
• 11/6/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/29/2024 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

FibroGen Stock Performance

FGEN stock opened at $0.48 on Tuesday. FibroGen, Inc. has a one year low of $0.18 and a one year high of $2.93. The stock has a market capitalization of $48.37 million, a P/E ratio of -0.39 and a beta of 0.82. The company has a 50 day moving average price of $0.36 and a two-hundred day moving average price of $0.55.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.21. The business had revenue of $46.33 million during the quarter, compared to analysts’ expectations of $34.00 million. During the same quarter last year, the firm earned ($0.52) EPS. Research analysts forecast that FibroGen, Inc. will post -0.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC raised its stake in shares of FibroGen by 34.4% during the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after purchasing an additional 860,854 shares during the period. Doheny Asset Management CA acquired a new position in FibroGen in the second quarter worth about $48,000. XTX Topco Ltd bought a new position in FibroGen during the 2nd quarter worth approximately $424,000. Sei Investments Co. grew its position in shares of FibroGen by 38.4% in the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 41,442 shares in the last quarter. Finally, Point72 DIFC Ltd increased its holdings in shares of FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 45,990 shares during the last quarter. Hedge funds and other institutional investors own 72.71% of the company’s stock.

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.